

## **Clinical Policy: Dimethyl Fumarate (Tecfidera), Diroximel Fumarate (Vumerity), Monomethyl Fumarate (Bafiertam)**

Reference Number: MDN.CP.PHAR.249

Effective Date: 04.01.2022

Last Review Date: 04.22

Line of Business: Meridian IL Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### **Description**

The following are nuclear factor-like 2 activators requiring prior authorization: dimethyl fumarate (Tecfidera<sup>®</sup>), diroximel fumarate (Vumerity<sup>®</sup>), and monomethyl fumarate (Bafiertam<sup>™</sup>).

### **FDA Approved Indication(s)**

Tecfidera, Vumerity, and Bafiertam are indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

### **Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Tecfidera, Vumerity, and Bafiertam are **medically necessary** when the following criteria are met:

### **I. Initial Approval Criteria**

#### **A. Multiple Sclerosis (must meet all):**

1. Diagnosis of one of the following (a, b, or c):
  - a. Clinically isolated syndrome;
  - b. Relapsing-remitting MS;
  - c. Secondary progressive MS;
2. Prescribed by or in consultation with a neurologist;
3. Age  $\geq$  18 years;
4. If request is for Vumerity, Bafiertam, or dimethyl fumarate there must be evidence of failure of Tecfidera used for  $\geq$  3 consecutive months, unless clinically significant adverse effects are experienced;
5. The requested agent is not prescribed concurrently with other disease modifying therapies for MS (*see Appendix D*);
6. Documentation of baseline number of relapses per year and expanded disability status scale (EDSS) score;
7. Dose does not exceed:
  - a. Starting dose: Tecfidera 240 mg (2 capsules) or Vumerity 462 mg (2 capsules) or Bafiertam 190 mg (2 capsules) per day for 7 days;

- b. Maintenance dose: Tecfidera 480 mg (2 capsules) or Vumerity 924 mg (4 capsules) or Bafiertam 380 mg (4 capsules) per day.

**Approval duration: 6 months**

**B. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. Multiple Sclerosis (must meet all):**

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member meets one of the following (a or b):
  - a. If member has received < 1 year of total treatment: Member is responding positively to therapy;
  - b. If member has received  $\geq$  1 year of total treatment: Member meets one of the following (i, ii, iii, or iv):
    - i. Member has not had an increase in the number of relapses per year compared to baseline;
    - ii. Member has not had  $\geq$  2 new MRI-detected lesions;
    - iii. Member has not had an increase in EDSS score from baseline;
    - iv. Medical justification supports that member is responding positively to therapy;
3. The requested agent is not prescribed concurrently with other disease modifying therapies for MS (*see Appendix D*);
4. If request is for a dose increase, new dose does not exceed Tecfidera 480 mg (2 capsules) or Vumerity 924 mg (4 capsules) or Bafiertam 380 mg (4 capsules) per day.

**Approval duration: 12 months**

**B. Other diagnoses/indications (must meet 1 or 2):**

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.  
**Approval duration: Duration of request or 6 months (whichever is less);** or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53 for Medicaid or evidence of coverage documents;
- B. Primary progressive MS.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

EDSS: expanded disability status scale  
 FDA: Food and Drug Administration  
 MS: multiple sclerosis

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Aubagio® (teriflunomide)	7 mg or 14 mg PO QD	14 mg/day
Avonex®, Rebif® (interferon beta-1a)	Avonex: 30 mcg IM Q week Rebif: 22 mcg or 44 mcg SC TIW	Avonex: 30 mcg/week Rebif: 44 mcg TIW
Betaseron® (interferon beta-1b)	250 mcg SC QOD	250 mg QOD
Plegridy® (peginterferon beta-1a)	125 mcg SC Q2 weeks	125 mcg/2 weeks
glatiramer acetate (Copaxone®, Glatopa®)	20 mg SC QD or 40 mg SC TIW	20 mg/day or 40 mg TIW
Gilenya® (fingolimod)	0.5 mg PO QD	0.5 mg/day
dimethyl fumarate (Tecfidera®)	120 mg PO BID for 7 days, followed by 240 mg PO BID	480 mg/day

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.*

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): known hypersensitivity to dimethyl fumarate, diroximel fumarate, or any of the excipients of Tecfidera, Vumerity, or Bafiertam; coadministration of Tecfidera, Vumerity, and Bafiertam
- Boxed warning(s): none reported

*Appendix D: General Information*

- Disease-modifying therapies for MS are: glatiramer acetate (Copaxone®, Glatopa®), interferon beta-1a (Avonex®, Rebif®), interferon beta-1b (Betaseron®, Extavia®), peginterferon beta-1a (Plegridy®), dimethyl fumarate (Tecfidera®), diroximel fumarate (Vumerity®), monomethyl fumarate (Bafiertam™), fingolimod (Gilenya®), teriflunomide (Aubagio®), alemtuzumab (Lemtrada®), mitoxantrone (Novantrone®), natalizumab (Tysabri®), ocrelizumab (Ocrevus®), cladribine (Mavenclad®), siponimod (Mayzent®), ozanimod (Zeposia®), and ofatumumab (Kesimpta®).
- Of the disease-modifying therapies for MS that are FDA-labeled for CIS, only the interferon products, glatiramer, and Aubagio have demonstrated any efficacy in decreasing the risk of conversion to MS compared to placebo. This is supported by the AAN 2018 MS guidelines.
- Tecfidera and Vumerity are both prodrugs of Bafiertam.

**V. Dosage and Administration**

Drug Name	Dosing Regimen	Maximum Dose
Dimethyl fumarate (Tecfidera)	Starting: 120 mg PO BID for 7 days Maintenance: 240 mg PO BID	480 mg/day
Diroximel fumarate (Vumerity)	Starting: 231 mg PO BID for 7 days Maintenance: 462 mg PO BID	924 mg/day
Monomethyl fumarate (Bafiertam)	Starting: 95 mg PO BID for 7 days Maintenance: 190 mg PO BID	380 mg/day

**VI. Product Availability**

Drug Name	Availability
Dimethyl fumarate (Tecfidera)	Delayed-release capsules: 120 mg, 240 mg
Diroximel fumarate (Vumerity)	Delayed-release capsule: 231 mg
Monomethyl fumarate (Bafiertam)	Delayed-release capsule: 95 mg

**VII. References**

1. Tecfidera Prescribing Information. Cambridge, MA: Biogen Inc.; January 2021. Available at <http://www.tecfidera.com>. Accessed February 8, 2021.
2. Vumerity Prescribing Information. Cambridge, MA: Biogen Inc.; January 2021. Available at <http://www.vumerity.com>. Accessed February 8, 2021.
3. Bafiertam Prescribing Information. High Point, NC: Banner Life Sciences LLC; April 2020. Available at: <https://bafiertam.com/prescribing-information> . Accessed February 8, 2021.
4. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018; 90(17): 777-788. Full guideline available at: <https://www.aan.com/Guidelines/home/GetGuidelineContent/904>.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created, adapted from CP.PHAR.249	04.01.22	04.22

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.